PrimeRFP SCOUT · Federal Contract Recompete Brief

75N93022C00061 — A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY.

A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY. is a federal NONE award for Department of Health and Human Services (HHS) held by REVAGENIX, INC.. Estimated value $28.2M ($28.2M obligated). Current period of performance ends Apr 25, 2028. Last award drew 30 bidders.

$28.2M
Estimated Value
Apr 25, 2028
PoP End / Expires
30
Bidders (last award)

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See related expiring contracts →

Analysis

Public

REVAGENIX, INC. holds $32.8M across 2 federal awards, concentrated at Department of Health and Human Services (HHS). Competition previously drew 30 offers. Set-aside status: NONE. Recompete timing centers on the Apr 25, 2028 PoP end — agencies typically plan 12–18 months ahead.

Contract facts

NONE
Contract number75N93022C00061
AgencyDepartment of Health and Human Services (HHS)
IncumbentREVAGENIX, INC.
UEID98QFZUPFXJ9
NAICS541715
PSCAN12
PoP end (current)Apr 25, 2028
Obligated$28.2M

A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY.

Recompete timing

Public
Expiring in 618 days

Current PoP ends Apr 25, 2028 (618 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Oct 25, 2026.

Watch this contract — one email →

Incumbent footprint

Public record

REVAGENIX, INC.$32.8M obligated across 2 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)
Department of Health and Human Services (HHS)$32.8M · 100% of firm total
Open full company profile

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See the recompete window for 75N93022C00061
More in SCOUT
Track this contract →

Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open REVAGENIX, INC.’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract 75N93022C00061?

75N93022C00061 (A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY.) is a Department of Health and Human Services (HHS) award with an estimated value of $28.2M, currently held by REVAGENIX, INC.. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on 75N93022C00061?

REVAGENIX, INC. is the incumbent with $32.8M across 2 related awards in SCOUT’s public footprint. The current period of performance ends Apr 25, 2028.

When does 75N93022C00061 come up for recompete?

SCOUT tracks a period-of-performance end of Apr 25, 2028. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75N93022C00061